- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Spinal muscular atrophy
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Nusinersen – November 2019
Nusinersen: Solution for injection 12 mg in 5 mL; Spinraza®
Last updated
20 March 2020